Biotechnology company MEDIPOST Inc said on Friday that it has submitted an Investigational New Drug (IND) amendment to the US Food and Drug Administration (FDA) to support the initiation of a Phase III clinical trial evaluating its investigational cell therapy targeting knee osteoarthritis.

The therapy is an allogeneic, umbilical cord blood-derived mesenchymal stem cell treatment designed to address symptomatic cartilage defects in affected patients.

Patient enrolment for the Phase III study is expected to begin in the first half of 2026.

Knee osteoarthritis remains a major cause of pain and mobility loss, underscoring the need for treatments that extend beyond symptom management. The trial aims to further evaluate the potential of regenerative cell therapy in meeting this clinical need.